The current invention concerns a composition for treating trauma in a subject, where the composition includes isolated mesenchymal stem cells (MSCs), wherein the MSCs are tenogenic-induced and/or chondrogenic-induced, and where the trauma is tendon trauma, traumas of the ligaments, or trauma of cartilage.

Disclosed are methods of ameliorating, inhibition, and/or reversing diabetes utilizing immune cells that have been reprogrammed ex vivo by contact with regenerative cells. In one embodiment said reprogrammed immune cells comprise peripheral blood mononuclear cells obtained from the patient in need of treatment wherein said cells are endowed with properties of immune modulation, and/or suppression of inflammation, and/or restoration of insulin sensitivity, and/or pancreatic regeneration. In one embodiment regenerative cells used for reprogramming are mesenchymal stem cells. In one particular embodiment said cells are umbilical cord derived mesenchymal stem cells. Culture of peripheral blood mononuclear cells together with said regenerative cells is performed in the presence of interleukin-2 and/or an mTOR inhibitor. In one embodiment said mTOR inhibitor comprises rapamycin and/or a derivative thereof.

Compositions and methods for treating neuronal injury, such as in Parkinson's disease, comprising administration of hematopoietic stem cells and mesenchymal stromal cells to a subject are provided. Methods for producing such compositions from blood, including umbilical cord blood are also provided.

The subject invention pertains to methods and devices for generating mature oocytes from immature oocytes and improving oocyte quality for improved success of assistant reproductive technology (ART). The methods include the use of tunneling nanotube-forming cells and oocytes, wherein the tunneling nanotube-forming cells transfer autologous genomic materials, biomolecules and cellular components to the oocytes. The devices of the invention include microfluidic device to improve the efficiency of the transfer of biomolecules and cellular components between tunneling nanotube-forming cells and oocytes.

Methods and products obtained from the method for isolating and culturing mixed populations of stem cells, making decellularized tissue matrix, making decellularized tissue matrix infused with said mixed populations of stem cells, and methods of stem cell therapy are provided.

The invention provides a method of producing and using extracellular vesicles (ECVs) derived from activated stromal cells for the treatment of certain disease and conditions. Specifically, ECVs derived from preactivated mesenchymal cells are effective in reducing cancer cell growth and metastasis as well as inducing tolerogenesis in immature dendritic cells. Additionally, ECVs derived from umbilical cord blood may be useful for immunosuppression and reduction of inflammation.

Methods and products obtained from the method for isolating and culturing mixed populations of stem cells, making decellularized tissue matrix, making decellularized tissue matrix infused with said mixed populations of stem cells, and methods of stem cell therapy are provided.

The current invention concerns a cell medium for in vitro inducing chondrogenesis or tenogenesis in mesenchymal stem cells (MSCs). The medium includes a glucose medium supplemented with at least one growth factor. The growth factor is selected from fibroblast growth factors (FGF) or transforming growth factors (TGF). FGF or TGF is present in a total concentration of between 1 and 15 ng/ml. In both cases, IGF can be added to enhance the induction process. In a further aspect, the invention provides for a use of such cell medium as well as a method for inducing isolated mesenchymal stem cells (MSCs) and a cell composition obtained by such method.

The invention relates to the field of genetic recombination and stein cell application. In particular, the invention provides a construct for expressing a soluble fragment of a secretory TRAIL, and a lentiviral expression vector comprising the construct. The present invention also provides a mesenchymal stein cell in which the construct is integrated into the genome, which can express and secrete the TRAIL fragment. The invention also provides the use of the construct or vector or mesenchymal stein cells for the treatment of brain tumors.

A cell medium for in vitro inducing chondrogenesis or tenogenesis in mesenchymal stem cells (MSCs). The medium is a glucose medium supplemented with at least one growth factor is chosen from the group of fibroblast growth factors (FGF) or the group of transforming growth factors (TGF), and the FGF or TGF is present in a total concentration of between 1 and 15 ng/ml. In both cases, IGF can be added to enhance the induction process. The use of the cell medium, a method for inducing isolated mesenchymal stem cells (MSCs) and a cell composition obtained by the method are also provided.